# A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

> **NCT00038545** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Filgrastim SD/01
- **DRUG:** Paclitaxel
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT00038545
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05-18
- **Primary completion:** 2004-04-27
- **Final completion:** 2004-04-27
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038545, "A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00038545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*